CTOs on the Move

3-V Biosciences

www.3vbio.com

 
3-V Biosciences, Inc. is discovering and developing therapeutics that modulate key pathways in oncology and infectious diseases. In oncology, the company`s lead candidate is a first-in-class, oral fatty acid synthase (FASN) inhibitor in Phase 1 clinical development that has been shown to block tumor cell signaling pathways and induce tumor cell apoptosis. 3-V`s antiviral therapeutics have demonstrated the ability to block host-pathogen interactions, resulting in robust and broad-spectrum in vitro and in vivo antiviral activity, including efficacy against viruses resistant to other classes of antiviral drugs, and a high barrier to resistance. The 3-V team applies an integrated approach, leveraging ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.3vbio.com
  • 1050 Hamilton Court
    Menlo Park, CA USA 94025
  • Phone: 650.561.8600

Executives

Name Title Contact Details

Funding

3-V Biosciences raised $18M on 02/13/2019

Similar Companies

Rainin Instrument

Rainin Instrument is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arteriocyte, Inc.

Arteriocyte, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Ambulatory Services of America Inc

Ambulatory Services of America Inc is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

MediWound

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. Specializing in the development, production and commercialization of solutions that seek to replace existing standards of care, the Company is committed to providing rapid and effective biologics that improve patient experiences and outcomes, while reducing costs and unnecessary surgeries. MediWounds first drug, NexoBrid®, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Utilizing the same core biotherapeutic enzymatic platform technology, MediWound has developed a strong R&D pipeline including the Companys lead drug under development, EscharEx®. EscharEx is a Phase III-ready biologic for debridement of chronic wounds with significant advantages over the $300 million monopoly legacy drug and an opportunity to expand the market. MediWounds pipeline also includes MW005, a topical therapeutic for the treatment of basal cell carcinoma that has demonstrated positive results in a recently completed Phase I/II study. For more information visit www.mediwound.com